LEXXW - Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
(TheNewswire)
Lexaria currently holding 46 grantedpatents worldwide
Kelowna, British Columbia – July 8,2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX &LEXXW) (the “Company” or “Lexaria”), a global innovator indrug delivery platforms announces three new patent awards.
In the European Union, the Company has received a newgranted patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery ofLipophilic Active Agents. This is theCompany’s second granted patent in this patent family with anearlier patent granted in Canada. This patent will expire in 2039,if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain,Sweden and Switzerland.
In Canada, Lexaria has received a new granted patent inpatent family #18: Compositions and Methods for Enhanced Delivery of AntiviralAgents . This is the Company’s fourth grantedpatent in this patent family which was previously granted in the US,Australia, and Japan. This patent will expire in 2041 if notextended.
This patent builds on original researchconducted by Lexaria in 2021 whereinthe Company evidenced in animal studies that DehydraTECH processing offive different antiviral drugs belonging to three classes of drugs(Protease Inhibitors, Reverse Transcriptase Inhibitors, and TubulinPolymerization and Microtubule Inhibitor) all were delivered intobloodstream at rates from 42% improvement to 204% improvement,compared to the same drugs not processed with DehydraTECH.
Building on prior patent success in the US related toepilepsy, Lexaria has received its fourth granted US patent in patentfamily #24, Compositions andMethods for Treating Epilepsy . This patent complements earlierresearch that discoveredDehydraTECH-CBD was capable of mitigating epileptic seizures inrodents, and was also absorbed into the bloodstream more effectivelythan the commercially available cannabinoid-based anti-seizuremedication, Epidiolex®. This patent will expire in 2044 if notextended.
With the issuance of these three new patents,Lexaria’s patent portfolio has now grown to 46 granted patentsworldwide. Lexaria’s intellectual property remains a significantcomponent in supporting future business objectives.
About Lexaria Bioscience Corp. &DehydraTECH
DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the wayactive pharmaceutical ingredients (APIs) enter the bloodstream throughoral delivery. Since 2016, Lexaria has developed and investigatedDehydraTECH with a variety of beneficial molecules in oral and topicalformats. DehydraTECH has repeatedly demonstrated the ability toincrease bio-absorption and has also evidenced an ability to deliversome drugs more effectively across the blood brain barrier, whichLexaria believes to be of particular importance for centrally activecompounds. Lexaria operates a licensed in-houseresearch laboratory and holds a robust intellectual property portfoliowith 46 patents granted and many patents pending worldwide. For moreinformation, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties, and there can be noassurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements. As such, you should not place undue reliance on theseforward-looking statements. Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings with the US Securities andExchange Commission on EDGAR. The Company provides links tothird-party websites only as a courtesy to readers and disclaims anyresponsibility for the thoroughness, accuracy or timeliness ofinformation at third-party websites. There is no assurance that any ofLexaria’s postulated uses, benefits, or advantages for the patentedand patent-pending technology will in fact be realized in any manneror in any part. No statement herein has been evaluated by the Food andDrug Administration (FDA). Lexaria-associated products are notintended to diagnose, treat, cure or prevent any disease. Anyforward-looking statements contained in this release speak only as ofthe date hereof, and the Company expressly disclaims any obligation toupdate any forward-looking statements or links to third-party websitescontained herein, whether as a result of any new information, futureevents, changed circumstances or otherwise, except as otherwiserequired by law.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2024 TheNewswire - All rights reserved.